EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Type and dose of gonadotropins in poor ovarian responders: does it matter?

Liese Boudry iD, Annalisa Racca, Herman Tournaye, Christophe Blockeel

Therapeutic Advances in Reproductive Health · 2021-01 · 15

DOI: 10.1177/26334941211024203 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Reproductive Health, online erschienen am 27.06.2021. Verfasst von Liese Boudry und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, 1090, Brussels, Belgium. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infertile patients with a diminished ovarian reserve, also referred to as poor ovarian responders, constitute a substantial and increasing population of patients undergoing in vitro fertilization. The management of patients with poor ovarian response is still a controversial issue. Almost a century has passed since the introduction of the first gonadotropin. A broad collection of urinary and recombinant gonadotropins, including biosimilars, is commercially available now. Despite great advances in assisted reproductive technology, there remains uncertainty about the optimal treatment regimen for ovarian stimulation in poor ovarian responders. Although oocyte donation is the most successful and ultimate remedy for poor ovarian responders, most patients persist on using their own oocytes in several attempts, to achieve the desired pregnancy. The aim of this review is twofold: first, to provide an overview of the commercially available gonadotropins and summarize the available evidence supporting the use of one or another for ovarian stimulation in poor ovarian responders, and second, to address the controversies on the dosage of gonadotropins for this specific in vitro fertilization population.

Schlagwörter

Stichwörter der Autor:innen

gonadotropin dosegonadotropinsovarian stimulationpoor ovarian responder

Autor:innen und Institutionen

  • Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, 1090, Brussels, Belgium.
  • Department of Obstetrics, Gynecology and Reproduction, Hospital Universitari Dexeus, Barcelona, Spain.
  • Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium; Department of Obstetrics, Gynecology, Perinatology and Reproduction, Institute of Professional Education, Sechenov First Moscow State…
  • Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium; Department of Obstetrics and Gynaecology, University of Zagreb, Zagreb, Croatia.

ORCID-Profile: Liese Boudry

Zitieren

APA

Boudry, L., Racca, A., Tournaye, H., & Blockeel, C. (2021). Type and dose of gonadotropins in poor ovarian responders: does it matter?. Therapeutic Advances in Reproductive Health, 15. https://doi.org/10.1177/26334941211024203

Vancouver

Boudry L, Racca A, Tournaye H, Blockeel C. Type and dose of gonadotropins in poor ovarian responders: does it matter?. Therapeutic Advances in Reproductive Health. 2021;15. doi:10.1177/26334941211024203

BibTeX
@article{Boudry2021,
  author = {Boudry, Liese and Racca, Annalisa and Tournaye, Herman and Blockeel, Christophe},
  title = {Type and dose of gonadotropins in poor ovarian responders: does it matter?},
  journal = {Therapeutic Advances in Reproductive Health},
  year = {2021},
  volume = {15},
  doi = {10.1177/26334941211024203}
}
Kostenlos starten →